On May 31, 2024, the FDA approved MRESVIA, an mRNA RSV vaccine manufactured by Moderna, for use in persons 60 years of age and older. The approval of MRESVIA was made by the FDA without referral to VRBPAC, its advisory committee charged with reviewing vaccines and related biological products prior to FDA licensing. Per the FDA, the referral was not made because the clinical trial design and study results “did not raise concerns or controversial issues that would have benefited from an advisory committee discussion.”
In June 2024, the CDC recommended use of the vaccine for persons 60 through 74 years considered at high-risk for severe lower respiratory tract infection from RSV illness and for all adults 75 years and older.
